ZA200500152B - Use of reboxetine for the treatment of hot flashes - Google Patents

Use of reboxetine for the treatment of hot flashes Download PDF

Info

Publication number: ZA200500152B
Authority: ZA; South Africa
Prior art keywords: use according; patient; reboxetine; hot flashes; cancer
Prior art date: 2002-08-14

Application number

ZA200500152A

Other languages

English (en)

Inventor

Fred Hassan

Original Assignee

Pharmacia & Upjohn Co Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-14

Filing date

2005-01-07

Publication date

2006-07-26

2005-01-07 Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc

2006-07-26 Publication of ZA200500152B publication Critical patent/ZA200500152B/en

Links

229960003770 reboxetine Drugs 0.000 title claims description 36
CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 title claims description 35
208000033830 Hot Flashes Diseases 0.000 title claims description 30
206010060800 Hot flush Diseases 0.000 title claims description 30
238000011282 treatment Methods 0.000 title claims description 6
239000003814 drug Substances 0.000 claims description 18
229940079593 drug Drugs 0.000 claims description 14
239000000651 prodrug Substances 0.000 claims description 10
229940002612 prodrug Drugs 0.000 claims description 10
150000001875 compounds Chemical class 0.000 claims description 8
150000003839 salts Chemical class 0.000 claims description 8
206010028980 Neoplasm Diseases 0.000 claims description 7
201000011510 cancer Diseases 0.000 claims description 7
208000024891 symptom Diseases 0.000 claims description 7
206010060862 Prostate cancer Diseases 0.000 claims description 4
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
230000009245 menopause Effects 0.000 claims description 4
238000002560 therapeutic procedure Methods 0.000 claims description 4
208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
206010057644 Testis cancer Diseases 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
238000001959 radiotherapy Methods 0.000 claims description 3
201000003120 testicular cancer Diseases 0.000 claims description 3
206010006187 Breast cancer Diseases 0.000 claims description 2
208000026310 Breast neoplasm Diseases 0.000 claims description 2
239000003098 androgen Substances 0.000 claims description 2
229940046836 anti-estrogen Drugs 0.000 claims description 2
230000001833 anti-estrogenic effect Effects 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
239000000328 estrogen antagonist Substances 0.000 claims description 2
230000003054 hormonal effect Effects 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
CBQGYUDMJHNJBX-OALUTQOASA-N (2S)-2-[(S)-(2-ethoxyphenoxy)-phenylmethyl]morpholine Chemical compound CCOC1=CC=CC=C1O[C@@H](C=1C=CC=CC=1)[C@H]1OCCNC1 CBQGYUDMJHNJBX-OALUTQOASA-N 0.000 claims 1
238000000034 method Methods 0.000 description 9
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 7
239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 7
239000000935 antidepressant agent Substances 0.000 description 6
229940005513 antidepressants Drugs 0.000 description 6
230000000694 effects Effects 0.000 description 6
CGTZMJIMMUNLQD-STYNFMPRSA-N (2r)-2-[(r)-(2-ethoxyphenoxy)-phenylmethyl]morpholine;methanesulfonic acid Chemical compound CS(O)(=O)=O.CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CGTZMJIMMUNLQD-STYNFMPRSA-N 0.000 description 5
229940088597 hormone Drugs 0.000 description 5
239000005556 hormone Substances 0.000 description 5
108010069236 Goserelin Proteins 0.000 description 4
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 4
108010000817 Leuprolide Proteins 0.000 description 4
229940123445 Tricyclic antidepressant Drugs 0.000 description 4
238000002483 medication Methods 0.000 description 4
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
239000003029 tricyclic antidepressant agent Substances 0.000 description 4
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
238000002657 hormone replacement therapy Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
229960002748 norepinephrine Drugs 0.000 description 3
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
239000000126 substance Substances 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
AHOUBRCZNHFOSL-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine Chemical compound C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
102000010909 Monoamine Oxidase Human genes 0.000 description 2
108010062431 Monoamine oxidase Proteins 0.000 description 2
GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 2
230000001078 anti-cholinergic effect Effects 0.000 description 2
230000001430 anti-depressive effect Effects 0.000 description 2
230000002146 bilateral effect Effects 0.000 description 2
238000013461 design Methods 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
229940011871 estrogen Drugs 0.000 description 2
239000000262 estrogen Substances 0.000 description 2
229960002913 goserelin Drugs 0.000 description 2
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
229960004338 leuprorelin Drugs 0.000 description 2
229940087857 lupron Drugs 0.000 description 2
239000002858 neurotransmitter agent Substances 0.000 description 2
238000011474 orchiectomy Methods 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 2
QYRYFNHXARDNFZ-UHFFFAOYSA-N venlafaxine hydrochloride Chemical compound [H+].[Cl-].C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 QYRYFNHXARDNFZ-UHFFFAOYSA-N 0.000 description 2
229940033942 zoladex Drugs 0.000 description 2
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 description 1
MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 description 1
TZJUVVIWVWFLCD-UHFFFAOYSA-N 1,1-dioxo-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzothiazol-3-one Chemical compound O=S1(=O)C2=CC=CC=C2C(=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 TZJUVVIWVWFLCD-UHFFFAOYSA-N 0.000 description 1
ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 1
241000906543 Actaea racemosa Species 0.000 description 1
206010001367 Adrenal insufficiency Diseases 0.000 description 1
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
-1 INTEGREX Chemical compound 0.000 description 1
206010027304 Menopausal symptoms Diseases 0.000 description 1
UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 description 1
244000131316 Panax pseudoginseng Species 0.000 description 1
235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
235000003140 Panax quinquefolius Nutrition 0.000 description 1
229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
235000015724 Trifolium pratense Nutrition 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000001800 adrenalinergic effect Effects 0.000 description 1
208000017515 adrenocortical insufficiency Diseases 0.000 description 1
230000002908 adrenolytic effect Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
230000000891 anti-reserpine Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
230000001713 cholinergic effect Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
235000005301 cimicifuga racemosa Nutrition 0.000 description 1
229960002896 clonidine Drugs 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
230000028436 dopamine uptake Effects 0.000 description 1
229940098766 effexor Drugs 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
235000008524 evening primrose extract Nutrition 0.000 description 1
229940089020 evening primrose oil Drugs 0.000 description 1
239000010475 evening primrose oil Substances 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
235000004426 flaxseed Nutrition 0.000 description 1
229960000389 fluoxetine hydrochloride Drugs 0.000 description 1
239000012458 free base Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
235000008434 ginseng Nutrition 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
230000000742 histaminergic effect Effects 0.000 description 1
238000001794 hormone therapy Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000002631 hypothermal effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229950003599 ipsapirone Drugs 0.000 description 1
208000012866 low blood pressure Diseases 0.000 description 1
QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
229960004090 maprotiline Drugs 0.000 description 1
238000013160 medical therapy Methods 0.000 description 1
229960004296 megestrol acetate Drugs 0.000 description 1
RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
229960003955 mianserin Drugs 0.000 description 1
239000000203 mixture Substances 0.000 description 1
230000002635 muscarinergic effect Effects 0.000 description 1
230000003551 muscarinic effect Effects 0.000 description 1
239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
230000002474 noradrenergic effect Effects 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
229960002296 paroxetine Drugs 0.000 description 1
229960005183 paroxetine hydrochloride Drugs 0.000 description 1
239000003075 phytoestrogen Substances 0.000 description 1
229940035613 prozac Drugs 0.000 description 1
230000005855 radiation Effects 0.000 description 1
229960003269 reboxetine mesylate Drugs 0.000 description 1
235000013526 red clover Nutrition 0.000 description 1
238000012552 review Methods 0.000 description 1
230000035807 sensation Effects 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000035900 sweating Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229960003991 trazodone Drugs 0.000 description 1
PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
230000000980 vagolytic effect Effects 0.000 description 1
229960002416 venlafaxine hydrochloride Drugs 0.000 description 1
229960001255 viloxazine Drugs 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Reproductive Health (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Toxicology (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

ZA200500152A 2002-08-14 2005-01-07 Use of reboxetine for the treatment of hot flashes ZA200500152B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US40354902P	2002-08-14	2002-08-14

Publications (1)

Publication Number	Publication Date
ZA200500152B true ZA200500152B (en)	2006-07-26

Family

ID=31888245

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200500152A ZA200500152B (en)	2002-08-14	2005-01-07	Use of reboxetine for the treatment of hot flashes

Country Status (14)

Country	Link
US (1)	US20040092519A1 (ko)
EP (1)	EP1530476A1 (ko)
JP (1)	JP2005537307A (ko)
KR (1)	KR20050049476A (ko)
CN (1)	CN1674907A (ko)
AU (1)	AU2003261185A1 (ko)
BR (1)	BR0313411A (ko)
CA (1)	CA2495452A1 (ko)
IL (1)	IL166266A0 (ko)
MX (1)	MXPA05001705A (ko)
NZ (1)	NZ537521A (ko)
PL (1)	PL373956A1 (ko)
WO (1)	WO2004016272A1 (ko)
ZA (1)	ZA200500152B (ko)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050080143A1 (en) *	2001-11-29	2005-04-14	Steiner Mitchell S.	Treatment of androgen-deprivation induced osteoporosis
US7524846B2 (en)	2003-10-14	2009-04-28	Wyeth	Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
US7491723B2 (en)	2003-10-14	2009-02-17	Wyeth	Alkanol and cycloalkanol-amine derivatives and methods of their use
US7550485B2 (en)	2003-10-14	2009-06-23	Wyeth	Substituted N-heterocycle derivatives and methods of their use
US7419980B2 (en)	2003-10-14	2008-09-02	Wyeth	Fused-aryl and heteroaryl derivatives and methods of their use
US7365076B2 (en)	2003-10-14	2008-04-29	Wyeth	Substituted aryl cycloalkanol derivatives and methods of their use
US7531543B2 (en)	2003-10-14	2009-05-12	Wyeth	Phenylpiperazine cycloalkanol derivatives and methods of their use
US7402698B2 (en)	2003-10-14	2008-07-22	Wyeth	Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
US7414052B2 (en)	2004-03-30	2008-08-19	Wyeth	Phenylaminopropanol derivatives and methods of their use
US7517899B2 (en)	2004-03-30	2009-04-14	Wyeth	Phenylaminopropanol derivatives and methods of their use
US20080033050A1 (en)	2006-08-04	2008-02-07	Richards Patricia Allison Tewe	Method of treating thermoregulatory disfunction with paroxetine
US20100069389A1 (en) *	2008-09-06	2010-03-18	Bionevia Pharmaceuticals, Inc.	Novel forms of reboxetine
CN104507465A (zh)	2012-06-08	2015-04-08	俄亥俄州立大学	使用生育三烯酚治疗灼伤和瘢痕损伤
CA2980990A1 (en) *	2015-04-07	2016-10-13	Meiji Co., Ltd.	Hot flash-suppressing agent

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL56369A (en) *	1978-01-20	1984-05-31	Erba Farmitalia	Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
GB8419683D0 (en) *	1984-08-02	1984-09-05	Erba Farmitalia	3-substituted derivatives of 1-amino-2-hydroxy-propane
US5464854A (en) *	1993-11-11	1995-11-07	Depadova; Anathony S.	Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S.
PL196996B1 (pl) *	1999-07-01	2008-02-29	Upjohn Co	Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku
PT1202725E (pt) *	1999-07-22	2007-07-11	Universuty Of Rochester	Método para tratar sintomas de alteração hormonal, incluindo afrontamentos.
CA2380373A1 (en) *	1999-08-13	2001-02-22	Seth Lederman	Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof
BR0115301A (pt) *	2000-11-15	2004-12-14	Lilly Co Eli	Uso de um inibidor seletivo da recaptação de norepinefrina
EP1383495A1 (en) *	2001-03-29	2004-01-28	Eli Lilly And Company	Duloxetine for treatment of hot flashes
DE10130020A1 (de) *	2001-06-25	2003-12-04	Gruenenthal Gmbh	Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
US6635675B2 (en) *	2001-11-05	2003-10-21	Cypress Bioscience, Inc.	Method of treating chronic fatigue syndrome
US20050009925A1 (en) *	2001-12-11	2005-01-13	Bymaster Franklin Porter	Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure

2003
- 2003-08-04 CN CNA038188341A patent/CN1674907A/zh active Pending
- 2003-08-04 US US10/633,762 patent/US20040092519A1/en not_active Abandoned
- 2003-08-04 PL PL03373956A patent/PL373956A1/xx not_active Application Discontinuation
- 2003-08-04 BR BR0313411-3A patent/BR0313411A/pt not_active IP Right Cessation
- 2003-08-04 WO PCT/US2003/022491 patent/WO2004016272A1/en not_active Application Discontinuation
- 2003-08-04 EP EP03788249A patent/EP1530476A1/en not_active Withdrawn
- 2003-08-04 CA CA002495452A patent/CA2495452A1/en not_active Abandoned
- 2003-08-04 MX MXPA05001705A patent/MXPA05001705A/es unknown
- 2003-08-04 JP JP2004529097A patent/JP2005537307A/ja active Pending
- 2003-08-04 KR KR1020057002435A patent/KR20050049476A/ko not_active Application Discontinuation
- 2003-08-04 NZ NZ537521A patent/NZ537521A/en unknown
- 2003-08-04 AU AU2003261185A patent/AU2003261185A1/en not_active Abandoned
2005
- 2005-01-07 ZA ZA200500152A patent/ZA200500152B/en unknown
- 2005-01-12 IL IL16626605A patent/IL166266A0/xx unknown

Also Published As

Publication number	Publication date
WO2004016272A1 (en)	2004-02-26
NZ537521A (en)	2007-05-31
EP1530476A1 (en)	2005-05-18
US20040092519A1 (en)	2004-05-13
MXPA05001705A (es)	2005-04-19
AU2003261185A1 (en)	2004-03-03
CA2495452A1 (en)	2004-02-26
IL166266A0 (en)	2006-01-15
BR0313411A (pt)	2005-06-28
CN1674907A (zh)	2005-09-28
PL373956A1 (en)	2005-09-19
KR20050049476A (ko)	2005-05-25
JP2005537307A (ja)	2005-12-08

Publication	Publication Date	Title
ZA200500152B (en)	2006-07-26	Use of reboxetine for the treatment of hot flashes
JP4925074B2 (ja)	2012-04-25	ミルタザピンと１種以上の選択的セロトニン再取り込み阻害剤とを含む医薬組成物
TWI330083B (en)	2010-09-11	Methods for treating or preventing symptoms of hormonal variations
EA003142B1 (ru)	2003-02-27	Лекарственное средство, обладающее антидепрессивным действием, его применение и способ лечения
JPS59193821A (ja)	1984-11-02	抗不安薬としてのフルオキセチンの使用法
KR20070007276A (ko)	2007-01-15	재발성 의학적 증상을 치료하기 위한 조성물 및 방법
JP2000505104A (ja)	2000-04-25	喘息の治療のためのロラタジンおよび充血除去剤を含む組成物
EP2542241B1 (en)	2016-04-27	Methods and compositions for treating or preventing symptoms of hormonal variations
US6500827B2 (en)	2002-12-31	Drug combinations
US20120010242A1 (en)	2012-01-12	Low dose pipamperone in treating mood disorders
Markov et al.	2010	Doxepin for insomnia
WO2007062837A2 (en)	2007-06-07	Use of a 5-ht4 agonist for the treatment of irritable bowel syndrome characterized by mixed or alternating bowel habits
TW383222B (en)	2000-03-01	Pharmaceutical composition of bicycloheptane derivatives
AU764579B2 (en)	2003-08-21	New drug combinations of a N.A.R.I., preferably reboxetine, and pindolol
KR20140098865A (ko)	2014-08-08	파록세틴으로 체온 조절 기능 이상을 치료하는 방법
JP2002511408A (ja)	2002-04-16	神経疾患のための新しい治療
TW200838524A (en)	2008-10-01	Methods for treating nasal congestion in hepatically impaired patients
MX2022006535A (es)	2022-09-09	Métodos para tratar síntomas de comportamiento y psicológicos en pacientes con demencia.
TW200906406A (en)	2009-02-16	Use of a compound that is a neurokinin A NK2 receptor antagonist for the preparation of medicaments for use in the prevention and treatment of sexual dysfunctions
Al-Doghether	2004	An overview of pharmacological aids available to enhance smoking cessation.
MXPA00010945A (en)	2001-07-31	New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol
WO2004037238A1 (en)	2004-05-06	New uses of deramciclane
CZ20004067A3 (cs)	2001-03-14	Nové kombinace léků N.A.R.I.(inhibitory reaktivace noradrenalinu), s výhodou reboxetinu, a pinodolu